- Home
- ARBE vs TRVI Comparison
ARBE vs TRVI Comparison
Compare ARBE & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBE
- TRVI
- Stock Information
- Founded
- ARBE 2015
- TRVI 2011
- Country
- ARBE Israel
- TRVI United States
- Employees
- ARBE N/A
- TRVI N/A
- Industry
- ARBE EDP Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ARBE Technology
- TRVI Health Care
- Exchange
- ARBE Nasdaq
- TRVI Nasdaq
- Market Cap
- ARBE 312.4M
- TRVI 341.4M
- IPO Year
- ARBE N/A
- TRVI 2019
- Fundamental
- Price
- ARBE $2.89
- TRVI $3.56
- Analyst Decision
- ARBE Strong Buy
- TRVI Strong Buy
- Analyst Count
- ARBE 2
- TRVI 8
- Target Price
- ARBE $3.00
- TRVI $9.31
- AVG Volume (30 Days)
- ARBE 19.2M
- TRVI 659.4K
- Earning Date
- ARBE 03-06-2025
- TRVI 03-19-2025
- Dividend Yield
- ARBE N/A
- TRVI N/A
- EPS Growth
- ARBE N/A
- TRVI N/A
- EPS
- ARBE N/A
- TRVI N/A
- Revenue
- ARBE $1,016,000.00
- TRVI N/A
- Revenue This Year
- ARBE $1.56
- TRVI N/A
- Revenue Next Year
- ARBE $395.31
- TRVI N/A
- P/E Ratio
- ARBE N/A
- TRVI N/A
- Revenue Growth
- ARBE N/A
- TRVI N/A
- 52 Week Low
- ARBE $1.40
- TRVI $1.30
- 52 Week High
- ARBE $5.09
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- ARBE 54.73
- TRVI 43.13
- Support Level
- ARBE $2.70
- TRVI $3.63
- Resistance Level
- ARBE $3.29
- TRVI $4.06
- Average True Range (ATR)
- ARBE 0.66
- TRVI 0.30
- MACD
- ARBE -0.01
- TRVI -0.11
- Stochastic Oscillator
- ARBE 33.13
- TRVI 0.44
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, USA, and others.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.